1-3 of 3
Reiji Fukano, MD PhD
Close
Sort by
Journal Articles

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Masahiro Sekimizu, MD PhD, Reiji Fukano, MD PhD, Ilseung Choi, MD PhD, Akiko Kada, PhD, Akiko Saito, MD, Ryuta Asada, PhD, Tetsuya Mori, MD PhD, Hirokazu Nagai, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2924.
https://doi.org/10.1182/blood-2018-99-112708
Published: 2018
Journal Articles

Outcome of 136 Children with Advanced Lymphoblastic Lymphoma Receiving an BFM-Type Therapy with Intensified Maintenance: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study

Shosuke Sunami, MD, PhD, Masahiro Sekimizu, MDPhD, Tetsuya Takimoto, MD,PhD, Tetsuya Mori, MD,PhD, Tetsuo Mitsui, MD, PhD, Reiji Fukano, MD, PhD, Takeshi Mori, MD, PhD, Atsushi Kikuta, MD PhD, Koh Katsuyoshi, MD,PhD, Toshihiko Imamura, MD, PhD, Akiko Moriya Saito, MD, PhD, Tomoyuki Watanabe, PhD, Kouichi Ohshima, MD, PhD, Junichiro Fujimoto, MD, PhD, Atsuko Nakazawa, MD, PhD, Ryoji Kobayashi, MD, PhD, Keizo Horibe, MD, Masahito Tsurusawa, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 3049.
https://doi.org/10.1182/blood.V124.21.3049.3049
Published: 2014
Journal Articles

The Clinical Features and Prognosis of Early T-Cell Precursor Subtype of Lymphoblastic Lymphoma in the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study

Reiji Fukano, MD PhD, Shosuke Sunami, MD PhD, Masahiro Sekimizu, MDPhD, Tetsuya Takimoto, Tetsuya Mori, MDPhD, Tetsuo Mitsui, MD PhD, Takeshi Mori, MD, PhD, Akiko Moriya Saito, MD PhD, Tomoyuki Watanabe, Koichi Ohshima, Junichiro Fujimoto, MD PhD, Atsuko Nakazawa, MD PhD, Nobutaka Kiyokawa, MD PhD, Ryoji Kobayashi, MD PhD, Keizo Horibe, MD PhD, Masahito Tsurusawa, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1728.
https://doi.org/10.1182/blood.V124.21.1728.1728
Published: 2014